The stock of Revance Therapeutics Inc. (NASDAQ:RVNC) last traded at $13.15, down -4.82% from the previous session.
Data from the available sources indicates that Revance Therapeutics Inc. (NASDAQ:RVNC) is covered by 12 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $65.00 and a low of $20.00, we find $37.50. Given the previous closing price of $13.81, this indicates a potential upside of 171.54 percent. RVNC stock price is now -33.58% away from the 50-day moving average and -51.39% away from the 200-day moving average. The market capitalization of the company currently stands at $1.19B.
In total, 2 analysts have assigned it a hold rating, and 9 have given it a buy rating. Brokers who have rated the stock have averaged $38.50 as their price target over the next twelve months.
With the price target maintained at $20, Exane BNP Paribas recently Upgraded its rating from Underperform to Neutral for Revance Therapeutics Inc. (NASDAQ: RVNC).
In other news, Moxie Dwight, SVP, GC & Secretary sold 11,000 shares of the company’s stock on Sep 06. The stock was sold for $187,704 at an average price of $17.06. Upon completion of the transaction, the SVP, GC & Secretary now directly owns 44,066 shares in the company, valued at $0.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 05, SVP, GC & Secretary Moxie Dwight sold 23,853 shares of the business’s stock. A total of $424,920 was realized by selling the stock at an average price of $17.81. This leaves the insider owning 55,066 shares of the company worth $0.72 million. Insiders disposed of 511,265 shares of company stock worth roughly $6.72 million over the past 1 year. A total of 1.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RVNC stock. A new stake in Revance Therapeutics Inc. shares was purchased by DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) during the first quarter worth $11,436,000. POINT72 ASSET MANAGEMENT, L.P. invested $8,892,000 in shares of RVNC during the first quarter. In the first quarter, UNISUPER MANAGEMENT PTY LTD acquired a new stake in Revance Therapeutics Inc. valued at approximately $4,176,000. M&G INVESTMENT MANAGEMENT LTD acquired a new stake in RVNC for approximately $3,235,000. RENAISSANCE TECHNOLOGIES LLC purchased a new stake in RVNC valued at around $2,767,000 in the second quarter. In total, there are 285 active investors with 89.40% ownership of the company’s stock.
With an opening price of $13.84 on Wednesday morning, Revance Therapeutics Inc. (NASDAQ: RVNC) set off the trading day. During the past 12 months, Revance Therapeutics Inc. has had a low of $11.10 and a high of $37.98. As of last week, the company has a debt-to-equity ratio of 14.77, a current ratio of 5.10, and a quick ratio of 4.70. The fifty day moving average price for RVNC is $19.56 and a two-hundred day moving average price translates $27.00 for the stock.
The latest earnings results from Revance Therapeutics Inc. (NASDAQ: RVNC) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.8, missing analysts’ expectations of -$0.78 by -0.02. This compares to -$0.88 EPS in the same period last year. The company reported revenue of $58.13 million for the quarter, compared to $28.37 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 104.93 percent. For the current quarter, analysts expect RVNC to generate $62.1M in revenue.
Revance Therapeutics Inc.(RVNC) Company Profile
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
